Neuren Pharmaceuticals
Home
About Us
Company Overview
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
Home
>
Investor Information
>
Corporate Governance
Font Smaller
Font larger
Print Page
Corporate Governance
Corporate Governance Statement
(0.07MB)
Code of Conduct
(0.10MB)
Securities Trading Policy
(0.08MB)
Audit Committee Charter
(0.09MB)
Remuneration Committee Charter
(0.08MB)
Risk Management Policy
(0.06MB)
Continuous Disclosure Policy
(0.11MB)
